From mild cognitive impairment to Alzheimer's disease - Influence of homocysteine, vitamin B 12 and folate on cognition over time: Results from one-year follow-up

Neurologia i Neurochirurgia Polska

Volumn 43, Issue 4, 2009, Pages 321-329

  Siuda, Joanna ^a   Gorzkowska, Agnieszka ^a   Patalong Ogiewa, Maja ^a   Krzystanek, Ewa ^a   Czech, Ewa ^b   Wiechuła, Barbara ^b   Garczorz, Wojciech ^b   Danch, Alojzy ^b   Jasińska Myga, Barbara ^a   Opala, Grzegorz ^a  

^a Katedra i Klinika Neurologii Wieku Podesz ego SAM SP Centralny Szpital Kliniczny ul Medyków 14   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Alipoproteine E4; Cognition disorders; Dementia; Homocysteine; Risk factors; Vascular diseases

Indexed keywords

APOLIPOPROTEIN E; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FEMALE; FOLIC ACID DEFICIENCY; GENE MUTATION; GENOTYPE; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; RISK FACTOR; VASCULAR DISEASE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CAUSALITY; COGNITION DISORDERS; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; HETEROZYGOTE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPERTENSION; MALE; POLAND; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 70449725117     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308. (Pubitemid 29120227)
2. Petersen R.C., Stevens J.C., Ganguli M., et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1133-1142.
3. Morris J.C., Storandt M., Miller J.P., et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol 2001; 58: 397-405. (Pubitemid 32217456)
4. Petersen R.C., Smith G.E., Ivnik R.J., et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995; 273: 1274-1278.
5. Amieva H., Letenneur L., Dartigues J.F., et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord 2004; 18: 87-93. (Pubitemid 38822744)
6. Tognoni G., Ceravolo R., Nucciarone B., et al. From mild cognitive impairment to dementia: a prevalence study in a district of Tuscany, Italy. Acta Neurol Scand 2005; 112: 65-71. (Pubitemid 41003363)
7. Goerlick P.B. Status of risk factors for dementia associated with stroke. Stroke 1997; 28: 459-463. (Pubitemid 27097022)
8. Ravaglia G., Forti P., Maioli F., et al. Conversion of mild cognitive impairment do dementia: predictive role of mild cognitive subtypes and vascular risk factors. Dement Geriatr Cogn Disord 2006; 21: 51-58. (Pubitemid 41797971)
9. Solfrizzi V., Panza F., Colacicco A.M., et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004; 63: 1882-1891. (Pubitemid 39532385)
10. Yener G.G., Ozturk V., Uzunel F., et al. Diagnosis profile and comparison of risk factors in mayor types of dementia: an hospital based study. J Neurol Sci 2004; 21: 301-310.
11. DeCarli C., Mungas D., Harvey D., et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63: 220-227. (Pubitemid 38971118)
12. Kivipelto M., Helkala E.L., Hanninen T., et al. Midlife vascular risk factors and late-life mild cognitive impairment. A population- based study. Neurology 2001; 56: 1683-1689. (Pubitemid 32574567)
13. Haviv Y.S., Shpichinetsky V., Goldschmidt N., et al. The common mutations C677T and A1298C in the human metylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 2002; 92: 120-126. (Pubitemid 34983885)
14. Religa D., Styczynska M., Peplonska B., et al. Homocysteine, apolipoproteine E and methylenetetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 2003; 16: 64-70. (Pubitemid 36677098)
15. Wright C.B., Lee H.S., Paik M.C., et al. Total homocysteine and cognition in tri-ethnic cohort. Neurology 2004; 63: 254-260.
16. Refsum H., Nurk E., Smith D., et al. The Hordaland Homocysteine Study: A community-based study of homocysteine, its determinants, and associations with diseases. J Nutr 2006; 136 (6 Suppl): 1731S-1740S. (Pubitemid 43765389)
17. McCaddon A., Hudson P., Davies G., et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001; 12: 309-313. (Pubitemid 32656662)
18. Schafer J.H., Glass T.A., Bolla K.I., et al. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc 2005; 53: 381-388. (Pubitemid 41623514)
19. Annerbo S., Wahlund L.O., Lokk J. The relation between homocysteine levels and development of Alzheimer's disease in mild cognitive impairment patients. Dement Geriatr Cogn Disord 2005; 20: 209-214. (Pubitemid 41291571)
20. Clark R., Smith D.A., Jobst K.A., et al. Folate, vitamin B12 and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol 1998; 55: 1449-1455.
21. Malouf M., Grimley E.J., Areosa S.A. Folic acid with or without vitamin B12 for cognition and dementia. Cochrane Database Syst Rev 2003; 4: CD004514.
22. Maluof A.M., Areosa S.A. Vitamin B12 for cognition. Cochrane Database Syst Rev 2003; 4: CD004326.
23. McMahon J.A., Green T.J., Skeaff C.M., et al. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med 2006; 354: 2764-2772. (Pubitemid 43974194)
24. Quadri P., Fragiacomo C., Pezzati R., et al. Homocysteine, folate and vitamin B12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80: 114-122. (Pubitemid 41115564)
25. th ed. American Psychiatric Association, Washington 1994.
26. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
27. Roman G.C., Tatemichi T.K., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-ARIEN International Workshop. Neurology 1993; 43: 250-260. (Pubitemid 23060253)
28. Saiki R.K., Levenson C.H., Ehrlich H.A. Genetic analysis of amplified DNA with immobilized sequence specific oligonucleotide probes. Proc Natl Acad Sci 1989; 86: 6230-6234.
29. Wolf H., Grunwald M., Ecke G.M., et al. The prognosis of mild cognitive impairment in the elderly. J Neural Transm Suppl 1998; 54: 31-50. (Pubitemid 28539341)
30. Modrego P.J., Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type. Arch Neurol 2004; 61: 1290-1293. (Pubitemid 39062687)
31. Barnes D.E., Alexopoulos G.S., Lopez O.L., et al. Depressive symptoms, vascular disease and mild cognitive impairment. Arch Gen Psychiatry 2006; 63: 273-280.
32. Gatz J.L., Tyas S.L., John P.S., et al. Do depressive symptoms predict Alzheimer's disease and dementia? J Gerontol 2005; 60: 744-747. (Pubitemid 40881181)
33. Gabryelewicz T., Styczyńska M., Łuczywek E., et al. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int J Geriatr Psychiatry 2007; 22: 563-567. (Pubitemid 46951755)
34. Ganguli M., Dodge H.H., Shen C., et al. Mild cognitive impairment, amnestic type. An epidemiologic study. Neurology 2004; 63: 115-121. (Pubitemid 38943788)
35. Farlow M.R., He Y., Tekin S., et al. Impact of APOE in mild cognitive impairment. Neurology 2004; 63: 1898-1901. (Pubitemid 39532387)
36. Traykov L., Rigaud A.S., Caputo L., et al. Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurol 1999; 6: 415-421. (Pubitemid 29371137)
37. Bednarska-Makaruk M., Broda G., Kurjata P., et al. Apolipoprotein E genotype, lipid levels and coronary heart disease in a Polish population group. Eur J Epidemiol 2001; 17: 789-792. (Pubitemid 34602348)
38. Bostom A.G., Silbershatz H., Rosenberg I.H., et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-1080. (Pubitemid 29230859)
39. Hogervorst E., Liberio H., Molyneux A., et al. Plasma homocysteine levels, cerebrovascular risk factors and cerebral white matter changes (leucoaraiosis) in patients with Alzheimer's disease. Arch Neurol 2002; 59: 787-793. (Pubitemid 34517761)
40. Postiglione A., Milan G., Ruocco A., et al. Plasma folate, vitamin B12, and total homocysteine and homozygosity for the C677T mutation of 5,10-metylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. Gerontology 2001; 47: 324-329. (Pubitemid 33135808)
41. Gussekloo J., Heijmans B.T., Slagboom P.E., et al. Thermolabile metylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85. J Neurol Neurosurg Psychiatry 1999; 67: 535-538. (Pubitemid 29438214)
42. Lewerin C., Matousek M., Steen G., et al. Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr 2005; 81: 1155-1162. (Pubitemid 41724959)